HomeQuestion

Would you consider switching capmatinib to tepotinib or vice versa due to grade 3 hepatotoxicity in a patient with metastatic NSCLC with MET Exon 14 skipping mutation?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In patients with stage III NSCLC who experience locoregional recurrence after neoadjuvant chemoimmunotherapy, surgery, and maintenance immunotherapy, and are treated with definitive chemoradiation at recurrence—what is the optimal systemic therapy strategy post-chemoradiation?

Would you consider bevacizumab for a patient with SCLC who has asymptomatic brain metastasis progression after CNS radiation while on maintenance immunotherapy?

How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?

Is there any antiresorptive therapy that you would be comfortable prescribing if the patient refuses to see a dentist for clearance and is at risk of skeletal-related events?

How do you approach the treatment of LS-SCLC after SBRT for a prior NSCLC in the ipsilateral lung?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.